Exodus Point Capital Management, LP Bellus Health Inc. Transaction History

Exodus Point Capital Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$7.14 - $8.53 $1.74 Million - $2.08 Million	-243,354 Reduced 48.43%	259,130 $1.87 Million
Q4 2022 Feb 13, 2023	BUY	$8.22 - $10.76 $2.45 Million - $3.2 Million	297,614 Added 145.27%	502,484 $4.13 Million
Q3 2022 Nov 10, 2022	BUY	$8.95 - $12.0 $1.83 Million - $2.46 Million	204,870 New	204,870 $2.16 Million
Q2 2022 Aug 19, 2022	SELL	$6.46 - $10.02 $2.95 Million - $4.57 Million	-456,143 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$5.56 - $7.99 $1.98 Million - $2.84 Million	355,227 Added 352.0%	456,143 $3.14 Million
Q4 2021 Feb 11, 2022	BUY	$5.26 - $8.3 $530,818 - $837,602	100,916 New	100,916 $812,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.